Latest News Archives - Pheno Therapeutics

Content Team In Clinical Trials, Latest News

Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802

UK MHRA grants CTA for first-in-human trial of a selective GPR17 antagonist Small molecule therapeutic designed for treatment of neurological diseases such as multiple sclerosis Edinburgh, UK January 14 2025 – Pheno Therapeutics Limited., a biotechnology company focused on the…

Content Team In Latest News, News

Professor Siddharthan Chandran featured in The Times discussing future prospects for Alzheimer’s patients

‘A blood test for Alzheimer’s — that’s a game-changer’ Siddharthan Chandran, head of the UK Dementia Research Institute, finds reasons to be hopeful, even if the NHS won’t offer the first ever treatment for the disease.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
__cf_bm	30 minutes	Cloudflare set the cookie to support Cloudflare Bot Management.

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Latest News

Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802

Professor Siddharthan Chandran featured in The Times discussing future prospects for Alzheimer’s patients

Pheno Therapeutics
Citypoint
3rd Floor
65 Haymarket Terrace
Edinburgh
UK
EH12 5HD

Privacy Policy

Cookies Policy

Manage Consent

Latest News

Pheno Therapeutics granted clinical trial authorisation for lead multiple sclerosis therapeutic candidate PTD802

Professor Siddharthan Chandran featured in The Times discussing future prospects for Alzheimer’s patients

Pheno Therapeutics Citypoint 3rd Floor 65 Haymarket Terrace Edinburgh UK EH12 5HD

Privacy Policy

Cookies Policy

Manage Consent

Pheno Therapeutics
Citypoint
3rd Floor
65 Haymarket Terrace
Edinburgh
UK
EH12 5HD